Company Profile

Mercury Therapeutics Inc
Profile last edited on: 4/24/19      CAGE: 5FWB8      UEI:

Business Identifier: Protein kinase drugs for cancer and metabolic disorders
Year Founded
1996
First Award
2004
Latest Award
2014
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2e Gill Street
Woburn, MA 01801
   (781) 932-1125
   N/A
   N/A
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Mercury Therapeutics, Inc. (“MTI”) had been a biopharmaceutical company focused on developing breakthrough treatments for cancer and metabolic disease. MTI’s expertise lay in developing small molecule drugs against targets in the signal transduction pathways that control tumor growth and energy metabolism. The Company had proprietary lead generation programs that target the Ras-MAP Kinase pathway in cancer and AMP activated protein kinase for diabetes and the Metabolic Syndrome. In late 2002, Mercury acquired exclusive, worldwide rights to an oncology-drug technology from Massachusetts General Hospital. The firm is focused on using the technology to develop small-molecule inhibitors to the Ras-Raf protein interaction. The firm also had a multi-year collaboration with Aventis and an exclusive license agreement with Debiopharm Group for the development and commercialisation of Debio 0930, a small molecule activator of AMPK (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases. With the intimely death of the founder of the firm, Mercury Therapeutics ceased operation in

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $147,371
Project Title: A Novel; Orally Available Small Molecule Ampk Activator As a Treatment for Non Al
2004 1 NIH $181,830
Project Title: Development of Inhibitors of B-Raf to Treat Melanoma

Key People / Management

  John M Kyriakis -- Founder and Vice President for Research